tbuckley/cabot-search huggingface dataset:
Abstract 3834: The National Biomarkers Development Alliance (NBDA): A comprehensive solution
Authors: Carolyn C. Compton, The NBDA Team
Journal: Cancer Research (2014)

Abstract The development of effective and robust biomarkers is essential to the realization of the vision of precision medicine. Despite huge investments in biomarker discovery and development over decades, less than 100 biomarkers are used routinely in clinical medicine; and approximately 1.3 new protein biomarkers are approved per year by FDA - extremely few new biomarkers are approved by the FDA each year. At present, the high costs and failure rates in biomarker development represent one of the most significant roadblocks to medical progress. The biomarker development process itself requires re-engineering to reduce the massive inefficiencies, fragmentation, and failure rates that now characterize the system. The NBDA is a nonprofit organization of academic, industry and government partners which aims to create a standards-based, comprehensive end-to-end approach to the development of biomarkers of different categories within a given context of use, guided throughout the development pipeline by regulatory and clinical implementation requirements. The NBDA will work with multi-sector stakeholders across the biomarker development continuum to identify where in the process standards matter, determine the status of existing standards and identify gaps, aggregate information referable to specific biomarkers and biomarker classes, and reproduce the work. NBDA will publish the recommendations it develops by consensus and science, building on the best of current practices. It will act in consultation with the FDA and professional standards organizations in order to meet the levels of evidence for biomarker qualification by regulators and validation in clinical use. Through standards and quality management approaches, it will link and integrate discovery, pre-clinical development, assay development and performance, clinical testing, regulatory approval, and post-market applications. Pilot projects in development are focused on newer classes of biomarkers: e.g., genomic biomarkers such as allelic variance as determined by next generation sequencing technologies; proteomics biomarkers generated by mass spectroscopy; volumetric and functional imaging; and complex biomarkers defined as combinations of different classes of biomarkers, the useful value of which is determined computationally. The ever more rapid development of assay technologies dictates that standards that allow them to be applied successfully to biomarker development keep pace. This can only be accomplished through broad coordination of effort and consensus, which is the goal of the NBDA. Citation Format: Carolyn C. Compton, The NBDA Team. The National Biomarkers Development Alliance (NBDA): A comprehensive solution. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3834. doi:10.1158/1538-7445.AM2014-3834
Information epidemics, economics, and immunity on the internet
Authors: E. Coiera
Journal: BMJ (1998)

Information in practice p 1496 

For several years we have been warned of the internet's rapid growth and potential to spread poor information to the public.1 Now there are anecdotes of patients coming to harm because of information obtained on the internet.2 Are we witnessing the beginning of an epidemic of misinformation or nothing more than a variation of what is endemic? Patients have always obtained information outside the formal healthcare system. Perhaps now there is simply a new carrier called the internet, and nothing else has changed?

The truth is we know very little about epidemiology in medical informatics, so it is hard to identify which information processes lead to unfavourable health outcomes. Encouragingly, new studies show surprising regularities when we look at population behaviour on the internet.3 Perhaps we will soon inject information “tracers” into our information and communication systems and observe their effect as they course though the social decision making apparatus.

In the meantime we should do what we know best and focus on the public's health. Though there is poor quality health information on the internet, 4 5 no one has yet shown it has a positive or negative impact on public health outcomes. …
Abstract 12381: Advantage of Aortic Valve Reconstruction in Dynamic Changes of Aortic Annulus Assessed by Speckle Tracking Echocardiography After Aortic Valve Surgery
Authors: Go Hashimoto, Makoto Suzuki, Hisao Yoshikawa, Takenori Otsuka, Yukiko Isekame, Hiromasa yamashita, Masanori Shiba, Raisuke Iijima, Hidehiko Hara, Shigeyuki Ozaki, Masato Nakamura, Kaoru Sugi
Journal: Circulation (2014)

Introduction: It is reported that aortic valve reconstruction (AVrC) by using autologous pericardium is useful in patients with various aortic valve diseases. This method may be more effective in preserving the natural motion of the aortic valve annulus. Significant dynamic changes in the aortic annulus have previously been reported in animal models and clinical studies. The purpose of this study is to analize the cyclic changes of the aortic annulus using speckle-tracking trans-esophageal echocardiography in patients who underwent AVrC surgery. Methods: The subjects were 35 patients underwent AVrC surgery for aortic regurgitation or aortic stenosis and 40 controls. Cyclic aortic annulus diameter of the maximum and minimum diameters were determined from a speckle-tracking displacement curve (figure). These data was used to calculate the absolute change in the diameter of the aortic annulus, which was defined as the difference in diameters throughout the cardiac cycle. Results: There was significant difference between maximum and minimum aortic annulus diameter in AVrC group (18.7±3.0 mm vs 16.1±2.9 mm, p&lt;0.0001). There was significant difference in the maximum and minimum aortic annulus diameter in control group (22.9±2.7 mm vs 20.0±2.9 mm, p&lt;0.0001). AVrC group had significant cyclic change of aortic annulus as same as control group (AVrC group : 2.6±1.0 mm vs control group : 2.9±0.7 mm, p= NS). Conclusions: Our study suggests that dynamic changes of the aortic annulus occur in the cardiac cycle and can be measured using speckle-tracking trans-esophageal echocardiography. AVrC may preserve the coordination of the left ventricle, aortic annulus, sinus of Valsalva and aorta compared with conventional aortic valve replacement.
Abstract 2155: Outcome Following Admission to Cardiac Intensive Care Unit in Pediatric Patients With Acute Fulminant Myocarditis
Authors: Sarah A Teele, Catherine Allan, Peter C Laussen, Jane W Newburger, Kimberlee Gauvreau, Ravi R Thiagarajan
Journal: Circulation (2009)

Background: Acute fulminant myocarditis (AFM) is an aggressive form of myocarditis that can be life-threatening. Despite the severity of illness, patients (pts) who are adequately supported have a ...
Abstract # 20389: Serum- and Glucocorticoid-Regulated Kinase 1 Contributes to Adverse Electrical Remodeling by Regulating Cardiac Na+ Channels
Authors: Saumya Das, AibaTakeshi Aiba, Katherine Hessler, Michael Rosenberg, Chun Yang Xiao, Pablo Quintero, Filomena Ottaviano, Michael Morissette, Federica delMonte, Patrick Ellinor, Gordon F Tomaselli, Anthony Rosenzweig
Journal: Circulation (2010)
Lepirudin Anaphylaxis and Kounis Syndrome
Authors: Constantinos M. Koutsojannis, Nicholas G. Kounis
Journal: Circulation (2004)

Lepirudin Anaphylaxis and Kounis SyndromeTo the Editor:In an ongoing lepirudin pharmacosurveillance program, Greinacher et al 1 reported that 4 patients experienced fatal anaphylaxis after reexposure to lepirudin and died shortly after the onset of the event.Three patients died from acute cardiorespiratory arrest and 1 from acute myocardial infarction.These cases are characteristic examples of drug-induced Kounis syndrome 2 -the concurrence of allergic or hypersensitivity reactions with acute coronary syndromes. 3Kounis syndrome is caused by certain environmental exposures, poisons, and venoms; conditions such as angioedema, bronchial asthma, exercise-induced anaphylaxis, food allergy, idiopathic anaphylaxis, serum sickness, urticaria, and mastocytosis; drugs via inflammatory mediators such as histamine, tryptase, and chymase; and arachidonic acid products such as leukotrienes.There are several categories of drugs that are capable of inducing Kounis syndrome.These include antibiotics, analgesics, antineoplastics, contrast media, corticosteroids, intravenous anesthetics, nonsteroidal antiinflammatory drugs, skin disinfectants, thrombolytics, and others. 2Apart from lepirudin, thrombolytics that have been reported, so far, to induce Kounis syndrome are streptokinase and urokinase.Although the overall risk/benefit assessment of lepirudin as a treatment for heparin-induced thrombocytopenia remains favorable, preventive and therapeutic measures should be considered before any reexposure to lepirudin.These measures should include the following: first, skin testing as a mainstay consideration (skin testing for most drugs, including lepirudin, should be studied at concentrations of Յ10 -4 mol/L 4 ); second, antibody testing including ELISA and radioallergosorbent testing; and third, rapid epinephrine or other vasopressor administration.As the authors of the above paper 1 correctly concluded, lepirudin should only be given in an environment where treatment for any anaphylactic reaction is readily available.
Eyewitnesses to history and participants as well
Authors: Keith D. Lindor
Journal: Hepatology (2010)

Over our term as editors for HEPATOLOGY, we have published over 1,645 original research articles as well as 160 reviews and meeting proceedings. These publications were cited over 32,000 times, and over 5.2 million downloads occurred. We are grateful to our authors, reviewers, and, especially from my perspective, to our associate editors. The associate editors were comprised of a remarkable group of physician scientists. All of our associate editors, with the exception of Dr. Margaret Koziel, who was replaced by Dr. David Nelson, remained in this position for the entire term. During our tenure, this group of individuals undertook several professional moves, all for promotions, yet managed to maintain their excellent, timely overview of the flow of papers to and through the journal. During our term, we were privileged to be involved with a rapid evolution in discoveries regarding liver disease. We saw the emergence, in this journal, of descriptions of targeted therapy for hepatocellular cancer, the introduction of new treatments for hepatitis B and C, and new treatments for the complications of cirrhosis. We also saw more individualized medicine in hepatology with tests for interleukin-28B for interferon response and PNPLA3 for nonalcoholic fatty liver disease and hepatic fibrosis after liver transplant, as well as the rapid development of applications in the field of stem cell biology to liver disease. The introduction of Comments From the Editors, suggested by Dr. Greg Gores, and Master's Perspective, suggested by Dr. Saul Karpen, were new additions to the journal, but also ones for which we received many favorable comments. As one of the associate editors said: "This experience validated my feeling that we are members of a great group of very collaborative, smart, engaging, forward-thinking physician scientists," referring, namely, to you, the world's hepatology community. Thank you for the privilege of serving you as the editor of HEPATOLOGY over the past 5 years. I look forward to reading about the new developments in our field under the leadership of Dr. Michael Nathanson and his new editorial team.
Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment
Authors: T. Bacchetti, A. Campanati, G. Ferretti, O. Simonetti, G. Liberati, A.M. Offidani
Journal: British Journal of Dermatology (2013)

Background Psoriasis is a chronic, inflammatory skin condition associated with a high frequency of cardiovascular events. Modifications of plasma lipids, and an increase in the levels of biochemical markers of inflammation and lipid peroxidation have been reported in subjects with psoriasis, suggesting a relationship between psoriasis, inflammation and oxidative damage. Objectives To investigate whether modulation of inflammatory activity by tumour necrosis factor‐α inhibitors in patients with psoriasis is associated with modification of lipid profiles, oxidative stress and paraoxonase (PON)1 activity. Methods The levels of plasma lipids and lipoprotein(a), and the levels of the markers of inflammation and lipid peroxidation were evaluated in subjects with psoriasis (n =23) before and after 24 weeks of treatment with etanercept. In the same subjects plasma total antioxidant capacity and the activity of PON1, an antioxidant and anti‐inflammatory enzyme associated with the high‐density lipoproteins (HDLs), were investigated. Results The results showed that clinical improvement in patients with psoriasis treated with etanercept is associated with a reduction in the levels of inflammatory markers [C‐reactive protein (CRP)] and lipid peroxidation, and also with increased antioxidant capacity in the serum of patients with psoriasis. These modifications are associated with a significant increase in the activity of PON1. A significant increase in the PON1/CRP ratio has also been observed in patients with psoriasis after treatment. The significant inverse correlation between CRP and PON1 activity suggests a relationship between PON1 activity and inflammation. Conclusions Treatment with etanercept is associated with a reduction in lipid peroxidation and an improvement in HDL antioxidant and anti‐inflammatory properties.
Fourth Night on Call at the Rape Crisis Center
Authors: Caroline Brooks DuBois
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dead Man Talking
Authors: Howard J Osofsky
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 13346: Impact of Renal Function in Patients With Multi-Vessel Coronary Disease (MVD) on Long Term Mortality Following Coronary Artery Bypass Grafting (CABG) Compared With Percutaneous Coronary Intervention (PCI)
Authors: Hariharan Sugumar, Terase Lancefield, Stephen J Duffy, Angela L Brennan, Andrew E Ajani, Brian Buxton, Julian Smith, Christopher M Reid, Kerrie Charter, Gishel New, Thomas Yip, Omar Farouque, Melanie Freeman, Nick Andrianopoulos, David J Clark
Journal: Circulation (2011)

Background: Renal failure is an important predictor of mortality in patients with MVD who undergo coronary revascularization. We sought to determine if the degree of renal impairment affects long-term mortality based on choice of revascularization strategy. Method: We analysed 7,841 patients with MVD undergoing either CABG (n=6,739) or PCI (n=1,102) between 2004-2008, enrolled in two large multi-centre Australian registries. Patients were assigned to three groups using stratified propensity matching based on their estimated glomerular filtration rate (eGFR) at baseline; ≥60 (CABG=4,674 vs. PCI=839), 30-59 (CABG=1,799 vs. PCI=226) and <30ml/min/1.73m2 (CABG=266 vs. PCI=37) respectively. Shock, myocardial infarction (MI) <24 hours, previous CABG, valve surgery or PCI were exclusions. We compared Cox-proportional hazards-adjusted National Death Index-linked long-term mortality (mean 3.2 years). Results: In patients with eGFR30-59 and ≥60mL/min/1.73cm2, there were more women, octogenarians and recent MI in th...
An unusual reaction to cold: a sporadic case of familial polymorphous cold eruption?
Authors: None Urano, None Shikiji, None Sasaki, None Fukuhara, None Arase
Journal: British Journal of Dermatology (1998)

Journal Article An unusual reaction to cold: a sporadic case of familial polymorphous cold eruption? Get access Y. Urano, Y. Urano Department of Dermatology, School of Medicine, University of Tokushima, Kuramoto‐cho, Tokushima City 770–8503, Japan, YoshioUrano E‐mail: yurano@clin.med.tokushima‐u.ac.jp Search for other works by this author on: Oxford Academic Google Scholar T. Shikiji, T. Shikiji Department of Dermatology, School of Medicine, University of Tokushima, Kuramoto‐cho, Tokushima City 770–8503, Japan, Search for other works by this author on: Oxford Academic Google Scholar S. Sasaki, S. Sasaki Section of Dermatology, Health Insurance Naruto Hospital, Naruto City, Tokushima, Japan Search for other works by this author on: Oxford Academic Google Scholar K. Fukuhara, K. Fukuhara Department of Dermatology, School of Medicine, University of Tokushima, Kuramoto‐cho, Tokushima City 770–8503, Japan, Search for other works by this author on: Oxford Academic Google Scholar S. Arase S. Arase Department of Dermatology, School of Medicine, University of Tokushima, Kuramoto‐cho, Tokushima City 770–8503, Japan, Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 139, Issue 3, 1 September 1998, Pages 504–507, https://doi.org/10.1046/j.1365-2133.1998.02419.x Published: 01 September 1998
Brave, Waiting for Pasteur
Authors: B M Reilly
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PLASMA LIPOIDS IN ARTERIOSCLEROSIS OBLITERANS
Authors: NELSON W. BARKER
Journal: Annals of Internal Medicine (1939)

ExcerptThe pathogenesis of arteriosclerosis has been the subject of controversy for many years. Among certain investigators there has arisen the concept that the development of atheroma is associated with disturbances of lipoid metabolism. The chief reasons for this can be summarized as follows: Pathologists from the time of Virchow6have noted the presence of comparatively large amounts of both cholesterol and neutral fat in atheromatous formations even in their earliest stages of development. More recently Leary11, 12has concluded that the development of the entire picture of arteriosclerosis is associated with these lipoid deposits and subsequent reaction of the vascular...